| A mapping literature review of medical cannabis clinical outcomes and quality of evidence in approved conditions in the USA from 2016 to 2019 S Jugl, A Okpeku, B Costales, EJ Morris, G Alipour-Haris, ... Medical Cannabis and Cannabinoids 4 (1), 21-42, 2021 | 33 | 2021 |
| Much ado about dosing: the needs and challenges of defining a standardized cannabis unit S Jugl, R Sajdeya, EJ Morris, AJ Goodin, JD Brown Medical cannabis and cannabinoids 4 (2), 121-124, 2021 | 16 | 2021 |
| Developing and validating a natural language processing algorithm to extract preoperative cannabis use status documentation from unstructured narrative clinical notes R Sajdeya, MT Mardini, PJ Tighe, RL Ison, C Bai, S Jugl, G Hanzhi, ... Journal of the American Medical Informatics Association 30 (8), 1418-1428, 2023 | 7 | 2023 |
| Practice patterns and training needs among physicians certifying patients for medical marijuana in Florida R Sajdeya, A Shavers, J Jean-Jacques, B Costales, S Jugl, C Crump, ... Journal of primary care & community health 12, 21501327211042790, 2021 | 7 | 2021 |
| Priorities for medical marijuana research from the perspective of physicians, dispensary owners/staff, and patients: a survey study J Jean-Jacques, R Cook, AG Winterstein, A Goodin, JD Brown, S Jugl, ... Medical Cannabis and Cannabinoids 4 (2), 107-113, 2021 | 6 | 2021 |
| A Mapping Literature Review of Medical Cannabis Clinical Outcomes and Quality of Evidence in Approved Conditions in the USA from 2016 to 2019. Medical cannabis and cannabinoids … S Jugl, A Okpeku, B Costales, EJ Morris, G Alipour-Haris, ... | 5 | 2021 |
| A systematic review of evidence for cannabis and cannabinoids as adjuvant therapy in palliative and supportive oncology care. S Jugl, S Keshwani, L Adkins, CD Heldermon, A Winterstein, A Goodin Journal of Clinical Oncology 38 (15_suppl), 12091-12091, 2020 | 3 | 2020 |
| Climbing the Evidence Pyramid: Dosing Considerations for Medical Cannabis in the Management of Chronic Pain S Jugl, AJ Goodin, JD Brown Medical Cannabis and Cannabinoids 6 (1), 41-45, 2023 | 2 | 2023 |
| Clinical considerations for cannabis use and cardiovascular health R Sajdeya, S Jugl, R Cook, JD Brown, A Goodin Medical Cannabis and Cannabinoids 5 (1), 120-127, 2022 | 1 | 2022 |
| Chronische Herzinsuffizienz> Grundlage: Nationale VersorgungsLeitlinie Chronische Herzinsuffizienz–Langfassung, 3 S Jugl PHARMAKON 8 (5), 1-8, 2020 | 1 | 2020 |
| Therapeutische Leitlinien in der pharmazeutischen Praxis IS der Erkrankung | | 2024 |
| Protocol of a Combined Cohort and Cross-Sectional Study of Persons Receiving Medical Cannabis in Florida, USA: The Medical Marijuana and Me (M3) Study R Sajdeya, HJ Fechtel, G Spandau, AJ Goodin, JD Brown, S Jugl, ... Medical Cannabis and Cannabinoids 6 (1), 46-57, 2023 | | 2023 |
| Ectopic Pregnancy Risk and Levonorgestrel-Releasing Intrauterine Systems S Jugl, AG Winterstein JAMA 330 (4), 378-378, 2023 | | 2023 |
| Angststörungen S Jugl, C Arnold PHARMAKON 11 (3), 1-8, 2023 | | 2023 |
| Unipolare Depression S Jugl PHARMAKON 11 (1), 1-8, 2023 | | 2023 |
| Urtikaria S Jugl PHARMAKON 10 (5), 1-8, 2022 | | 2022 |
| A comprehensive review on the teratogenic risks for twelve drugs with risk evaluation and mitigation strategy (REMS) to prevent prenatal exposure TMI Aydogan, N Smolinski, T Thai, S Jugl, A Sarayani, C Ewig, ... PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 31, 151-151, 2022 | | 2022 |
| Utilization of biologics before, during and after pregnancy among patients with autoimmune conditions C Ewig, N Smolinski, Y Wang, T Thai, A Sarayani, S Jugl, S Rasmussen, ... PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 31, 263-263, 2022 | | 2022 |
| Morbus Crohn S Jugl PHARMAKON 10 (3), 1-8, 2022 | | 2022 |
| Reizdarmsyndrom S Jugl PHARMAKON 10 (1), 1-8, 2022 | | 2022 |
